A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
Phase of Trial: Phase III
Latest Information Update: 27 Nov 2017
At a glance
- Drugs Ozanimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Celgene Corporation; Receptos
- 04 May 2017 Planned primary completion date changed from 1 Jun 2020 to 31 May 2020.
- 20 Dec 2016 Status changed from active, no longer recruiting to recruiting.
- 20 Oct 2015 New trial record